Introduction
============

An interesting hypothesis concerning Alzheimer\'s disease (AD) development posits a cause--effect relationship between accumulation of mitochondrial DNA (mtDNA) mutations and neurodegenerative changes associated with this pathology, for example, defective oxidative phosphorylation, increased oxidative stress, accumulation of amyloid-ß (Aß) and apoptosis.[@b1],[@b2] Human cells contain thousands of mtDNA copies and the most common mutations are insertion, deletions, and point mutations that are classified as homoplasmic or heteroplasmic if they regard all mtDNA copies or only a fraction of them, respectively.[@b3] As regards homoplasmic point mutations, studies on association between mtDNA haplogroups and AD have not provided to date definite conclusions.[@b4],[@b5] In brains of patients with AD, heteroplasmic mutations are increased by 63% compared to controls,[@b6] while AD and elderly subjects show a higher aggregate burden of low-level heteroplasmic point mutations than younger subjects.[@b7] To further our understanding of allelic variations, we investigated in whole blood of AD patients and age-matched controls the quantitative levels of the four bases for each nucleotide position (np) on both strands of the entire sequence of mtDNA by the resequencing array MitoChip v2.0 which allows analysis of mtDNA sequences with high reproducibility and sensitivity.[@b8],[@b9]

Materials and Methods
=====================

Subjects
--------

This study included a total of 18 AD patients and 18 age-matched controls enrolled from October 2009 to September 2010 at the INRCA Geriatrics Unit of Fermo. A priori power analysis, performed by one-sided *t*-test with 5% significance level, indicated that a sample size of 36 subjects (18 AD and 18 controls) provides ∼80% of power to detect differences among groups. The research was approved by the Institutional Ethical Committee and each participant or caregiver provided informed consent to participate. Patients were diagnosed according to National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer\'s Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD by an extended neuropsychological and functional evaluation, neuroimaging, and laboratory tests. Controls consisted of volunteers and spouses of the patients and underwent the same assessment as the AD group (Table [1](#tbl1){ref-type="table"}).

###### 

Characteristics of the study subjects

                 AD patients   Controls      *P* value
  -------------- ------------- ------------- -----------
  Age            76.0 ± 1.24   74.1 ± 1.46   0.328
  Gender (M/F)   3/15          4/14          0.674
  MMSE           18.2 ± 1.01   28.0 ± 0.22   \<0.001
  ADL            5.4 ± 0.26    6.0 ± 0.00    0.039
  IADL           3.7 ± 0.43    8.0 ± 0.00    \<0.001

Values are expressed as mean ± standard error of the mean (SEM). *P* values have been calculated by *t*-test except for the comparison of gender where *χ*^2^ has been applied.

MitoChip v2.0 resequencing array protocol
-----------------------------------------

Total DNA was extracted from whole blood using QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany) and amplified by REPLI-g mitochondrial DNA kit (Qiagen, Hilden, Germany). After purification, DNA was quantified spectrophotometrically and Genechip Resequencing array kit (Affymetrix, Santa Clara, CA) was employed for fragmentation and labeling. After loading, MitoChip arrays were washed and stained in Fluidics Station 450 and scanned in Affymetrix GeneChip Scanner 3000 7G.

MitoChip v2.0 array analysis
----------------------------

Affymetrix MitoChip v2.0 is a mtDNA sequencing array with eight 25-mer probes/base position (four oligonucleotide probes/strand) corresponding to the whole revised Cambridge Reference Sequence (rCRS). Each 25-mer probe is varied at the central position to incorporate each possible nucleotide (A, G, C, or T). Data acquisition was performed using the Affymetrix Genechip Command Console (AGCC) software and analysis was carried out with GSEQ 4.1. Output files utilized for this study were the Single Nucleotide Polymorphism (SNP) View and Probe Intensity Files that provide, for each np, the base call classified as homoplasmic or heteroplasmic and value of fluorescence intensity of the four bases for both sense and antisense filaments. The quantitative estimates of allelic contribution were used to calculate REA (Ratio of Expected Allele) index, which is the log ratio of the signal intensity of the reference allele at any site, as indicated in the rCRS, to the average signal intensity of the other three alleles from the sense and antisense strand.[@b10] A high value of the index suggests that the reference allele is prevailing, while a low value indicates that the contribution of the other alleles is significant.

Statistical analysis
--------------------

Statistical analysis was performed as follows. First, one-sided *t*-test (*P* ≤ 0.02) was used to identify differences among REA values in the two groups for every np. According to correction for multiple testing, we calculated the *q* values with FDR (false discovery rate) method by QVALUE software with a significant threshold of 0.05.[@b11] Second, principal component analysis (PCA) was applied on a restricted set of nps (*n* = 34) with the lowest *P*-values (*P* \< 0.01) between AD and controls.[@b12] The eigenvalues \>1.0 were retained in the analysis and a Varimax orthogonal rotation was used to obtain the factors. To interpret the results from factor analysis, the pattern of the factor loading was examined to determine which original variables represented primary constituents of each factor. An absolute loading value ≥0.85 was used to select REAs useful for cluster analysis. Third, receiver operating characteristic (ROC) curves were calculated to estimate the area under the curve (AUC) for selected REAs with *P* \< 0.01 in relation to disease. AUC values ≥0.80 were taken into account for cluster analysis. Finally, hierarchical clustering was performed based on Euclidean distance between AD and control samples with complete linkage method. The linear discriminant analysis was adopted to verify the "goodness" of the classification. Contingency analyses were applied to examine frequency distributions.

Results
=======

We compared REA values for each site between AD patients and controls and identified 270 nps with *P* ≤ 0.02 by *t*-test ([Table S1](#SD2){ref-type="supplementary-material"}). All the 270 nps had a *q* value \<0.05 and therefore were considered truly significant. These sites, numbered according to GenBank position and ID number, were not associated with homo- or heteroplasmic mutations, with the exception of three cases, each of which regarded only one subject: nps 4762 (ID 49, heteroplasmic mutation in controls), 5489 (ID 93, heteroplasmic mutation in AD), and 13035 (ID 109, homoplasmic mutation in AD). It should be evidenced that GSEQ 4.1 software assigns heteroplasmy calls when there are two different bases with fluorescence intensity values close to each other, resembling the diploid condition with about 50% heteroplasmy.[@b9],[@b13] The most remarkable result was that all but one (np 4762, ID 49) of the 270 nps displayed the highest value for controls ([Figure S1](#SD1){ref-type="supplementary-material"}). This means that controls had a notably higher fidelity to reference base than AD patients, which consequently showed a significant degree of allelic shift. [Table S1](#SD2){ref-type="supplementary-material"} shows the amino acid changes when the reference base is substituted by one of the other bases and substitutions resulting in nonsynonymous mutations were significantly more abundant than the synonymous ones (*χ*^2^ test; *P* \< 0.001). The 270 nps did not belong to a particular gene, suggesting random nucleotide variation (Table [2](#tbl2){ref-type="table"}). [Table S2](#SD3){ref-type="supplementary-material"} reports the six factors identified by PCA applied to the 34 most significant nps (*P* \< 0.01). Factorial weights ≥0.85 were selected in order to identify REAs that had a very high correlation with factors. Thus, nps 2620, 1414, 6226, and 13016 were considered important for discriminating healthy subjects and AD patients. Diagnostic accuracy of REA values was evaluated with ROC curve analyses ([Table S3](#SD4){ref-type="supplementary-material"}). When comparing AD versus controls, np 16195 showed the highest value of AUC (0.804). Hierarchical cluster analysis including nps 2620 (16S), 1414 (12S), 6226 (COI), 13016 (ND5), and 16195 (D-Loop) showed that groups were related to the selected REAs and the percentage of cases correctly classified was 80% (Fig. [1](#fig01){ref-type="fig"}). There was no prevalence of a specific gene or a functional gene class in the selected nps (Monte Carlo analysis; *P* = 1.000). We calculated the percentage of heteroplasmy for these nps according to Coon et al.,[@b10] and found that these values were between 6.32% and 15.9%, corresponding to low-level heteroplasmy. Higher heteroplasmy percentage values were found in AD subjects compared to controls, for each discriminant site, but the comparisons resulted significant only for 16195 (one-sided *t*-test; *P* \< 0.05). Data discussed here were deposited in NCBI\'s Gene Expression Omnibus,[@b14] and are accessible through GEO Series accession number GSE49160 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49160>).

###### 

Nps for each gene counted in the 270 REAs with *P* \< 0.02 (*t*-test)

  Genes                nps   *P* value
  -------------------- ----- -----------
  D-loop               26    0.854
  tRNA phenylalanine   1     1.000
  12S                  17    1.000
  16S                  39    0.152
  tRNA leucine 1       6     0.128
  ND1                  14    0.579
  tRNA methionine      1     1.000
  ND2                  25    0.346
  tRNA asparagine      3     0.616
  tRNA cysteine        1     1.000
  COI                  26    1.000
  tRNA serine 1        1     1.000
  tRNA aspartic acid   3     0.616
  COII                 5     0.115
  Non coding           3     0.247
  tRNA lysine          1     1.000
  ATPase8              3     1.000
  ATPase6              4     0.073
  COIII                11    0.539
  ND3                  5     1.000
  ND4                  18    0.420
  tRNA histidine       1     1.000
  ND5                  31    0.893
  ND6                  7     0.805
  tRNA glutamic acid   1     1.000
  Cytb                 17    0.610

Statistical analysis shows that these nps are randomly distributed among genes (*χ*^2^ test).

![Hierarchical clustering of REA values for the selected nps (2620, 1414, 6226, 13016, and 16195) well divided the AD patients from control subjects. The discriminant analysis showed that the percentage of cases correctly classified was 80% (*n* = 36 individuals). Applying bootstrap method with 10,000 resampling we found that the 99% CI of percentage of correct classification was between 72% and 94%. We found in the dendrogram a percentage of subjects correctly classified corresponding to 78% that is within the CI defined by bootstrap. CTR, control group; AD, Alzheimer\'s disease patients.](acn30001-0284-f1){#fig01}

Discussion
==========

Array-based analysis of mtDNA showed that AD whole blood is associated with an increased allelic shift compared to age-matched controls, and that some nps discriminate between the groups with 80% of cases correctly classified. Affymetrix MitoChip v2.0 provides the advantage of performing quantitative estimation for each of the four possible alleles in every np while avoiding interference of background nonspecific signal by setting specific conditions in GSEQ 4.1 algorithm. The sites with increased allelic shift in AD were not associated with homo- or heteroplasmic mutations, and conceivably their allelic imbalance has a limited phenotypic effect. However, many nucleotide substitutions alter protein structure and possibly function, and the aggregate burden of all variations may impact on mitochondria and cell oxidative capacity until exceeding the minimum threshold for a specific cell to function.[@b15] Indeed, results from AD cybrid model experiments indicate that, by introducing mitochondria from an AD donor into a clonal host cell depleted of endogenous mtDNA, an AD cybrid is obtained that exhibits reduced cytochrome c oxidase (COX) activity, increased oxidative stress, increased intracellular and extracellular ß-amyloid levels, and cell death activation compared to control cybrids.[@b16],[@b17] The nps included in hierarchical cluster analysis did not belong to a specific gene or a functional class of genes, they were selected for the best separation of the two groups of subjects. This apparent lack of spatial and functional linkage suggests that the allelic shift could be completely random and unspecific. Unlike homoplasmic and many heteroplasmic mutations that are inherited or acquired at early stages of development, these allelic alterations increases probably throughout life[@b18] and could eventually increase heteroplasmy levels. Engineered mice, heteroplasmic for NZB and 129S6 mtDNAs, showed impaired spatial memory retention and cognitive impairment, even at low-level heteroplasmy of NZB and 129S6 mtDNA genomes.[@b19] Our results support the hypothesis that mtDNA could accumulate mutations as a result of damage from reactive oxygen species, determining an impairment of oxidative phosphorylation and neurodegeneration. Actually, changes of oxidative markers such as 8-hydroxyguanosine, lipid peroxidation, nitration, and nucleic acid oxidation generally precede occurrence of Aß aggregates and hyper-phosphorylated tau protein, considered the hallmarks of AD.[@b20],[@b21] These observations strengthen the notion that mitochondria are a potential target for preventive intervention in AD.
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###### 

**Figure S1.** Line graphs of Alzheimer\'s disease patient (AD) and control (CTR) REA values for the nps reported in [Table S1](#SD2){ref-type="supplementary-material"}. Nps are represented with their corresponding ID. (A) Nps from 1 to 135 are represented. REAs for controls have the highest value except for np 4762 corresponding to ID 49. (B) Nps from 136 to 270 show the highest REA value for controls.

###### 

**Table S1.** Nps corresponding to significant comparisons of REA values between AD and controls with *P* ≤ 0.02 (*t*-test) sorted in ascending order of *P*. The reference base, the gene involved, as well as the possible amino acid change, are also indicated. Amino acid substitutions have been defined by MitoTool software.

###### 

**Table S2.** Factor loadings, identified by the Principal Component Analysis (PCA), of REA values corresponding to the 34 most significant nps (*P* \< 0.01). The percentage of explained variance was 32.6 for factor 1, 15.6 for factor 2, 12.5 for factor 3, 8.1 for factor 4, 7.6 for factor 5 and 6.3 for factor 6. In bold the nps selected for cluster analysis.

###### 

**Table S3.** ROC curve analysis of REA values corresponding to the 34 most significant nps (*P* \< 0.01). In bold the nps selected for cluster analysis.
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